AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New and Hot in Skin Cancer

Description

The discussion on skin cancer highlighted its significance in dermatology, presenting a dynamic landscape with over 5 million new cases expected in the U.S. annually. Key updates included new treatments for actinic keratoses, highlighting Turbinibulum for its less aggressive side effects, and advancements in photodynamic therapy (PDT), which showed efficacy with reduced pain when applied without incubation. An increased aggressiveness in actinic keratoses was noted in patients on calcium channel blockers, suggesting closer monitoring is necessary. The incidence of Merkel cell carcinoma continues to rise, with PD1 inhibitors now providing effective treatment options, although patients must be screened for comorbidities. Basal cell carcinoma treatments include Hedgehog inhibitors, with studies indicating potential benefits from treatment breaks due to side effects. For squamous cell carcinoma, genomic tests can better identify high-risk patients. Adjuvant and increasingly neoadjuvant therapies are becoming prominent in treatment frameworks. Melanoma rates are also increasing, now the fifth most common cancer in the U.S., yet challenges remain in effectively diagnosing and treating it, particularly invasive forms. The use of electrical impedance spectroscopy and genomic testing is emerging in clinical practice to enhance early diagnosis, overall demonstrating a pressing need for continued advancements in skin cancer management.

View more

Conclusions

  • Skin cancer, particularly melanoma, is on the rise in the United States, with significant public health implications.
  • Tirbanibulin represents a new and effective treatment for actinic keratosis with fewer side effects compared to traditional therapies.
  • Photodynamic therapy (PDT) can be effectively administered without the painful incubation period, thereby enhancing patient comfort.
  • There is an increased rate of actinic keratosis (AK) severity in patients using calcium channel blockers, indicating the need for more careful monitoring.
  • Merkel cell carcinoma cases have been increasing and require comprehensive screening for associated comorbidities.
  • Patients with Merkel cell carcinoma are at higher risk for subsequent malignancies, including melanoma and thyroid cancers.
  • Long-term UV phototherapy for psoriasis does not appear to significantly increase the risk of skin cancers such as melanoma and non-melanoma skin cancer.
  • Hydrochlorothiazide may be linked to an increased risk of squamous cell carcinoma and melanoma, particularly with long-term use.
  • Metformin has a potential role in reducing the risk of basal cell carcinoma, suggesting it may have chemoprotective properties.
  • The use of genomic tests such as 40-GEP can better predict metastatic risks in squamous cell carcinoma, improving patient management strategies.
  • Neoadjuvant therapy with cemiplimab shows promising results in achieving complete pathological responses in advanced cutaneous squamous cell carcinoma.
  • Psoriasis is associated with a small but significant increased risk of non-melanoma skin cancer, necessitating careful monitoring in affected individuals.
  • There is a need for improved diagnostic accuracy in melanoma detection, with technologies like electrical impedance spectroscopy offering promising results.
  • Genomics can play a critical role in the early detection and management of melanoma, with tests showing high negative predictive values.
  • Dao D-PD et al. 2021
  • Dlott AH et al. 2021
  • Miller et al. 2022
  • Kempers et al. 2020
  • Blauvelt et al, NEJM, 2021
  • Kaw et al, JAAD, 2020
  • Gioppo et al, Int J Dermatol, 2024
  • Jacobs et al, JAMA Dermatol, 2021
  • Weilandt et al, J Dtsch Dermatol Ges, 2024
  • Eid et al, JAMA Dermatol, 2023
  • Wang et al, JAAD, 2023
  • Mimouni et al, Photodermatol Photochem Photobiol, 2023
  • Azoulay et al, JAAD, 2023
  • Adalsteinsson et al, JAAD, 2021
  • Leow et al, Derm Therapy, 2021
  • Dinehart et al, SKIN J Cut Med, 2018
  • Lane et al, Oncotarget, 2021
  • Stratigos et al, Lancet Oncol, 2021
  • Lewis et al, SKIN, 2023
  • Migden et al. NEJM. 2018.
  • Wysong et al. JAAD 2021; Ibrahim et al. Future Oncology 2021.
  • Thatiparthi et al, Am J Clin Derm, 2021
  • Rigel et al, 2024
  • Siegel et al, Ca J Clinicians, 2024
  • ACS 2024
  • Welch et al, NJEM, 2021
  • Eriksson et al, Cancers, 2021
  • Soh et al, Dermatol Surgery, 2024
  • Kopf et al, Arch Dermatol, 1975
  • Friedman, R. J., & Kopf, A. W., et al. 1985.
  • Burshtein et al, Dermatol Surgery, 2024
  • Zakria et al, Melanoma Res, 2023
  • Puglisi R, et al. Cancers (Basel). 2021;13(12).
  • Ferris et al, Poster, WCMiami 2024; Gerami P, et al. J Am Acad Dermatol. 2017;76(1):114-120 e112; Skelsey M, et al. SKIN The Journal of Cutaneous Medicine. 2021;5(5):512-523.